γ-hydroxy-propyl oxazoline | 206859-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: γ-hydroxy-propyl oxazoline
• 英文别名: 3-(4,5-Dihydro-1,3-oxazol-2-yl)propan-1-ol
• CAS: 206859-45-2
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: VEERNCWDIVHRAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  γ-hydroxy-propyl oxazoline 、 丙烯酸 以81%的产率得到γ-hydroxy-(N-ethyl-2-acryloyloxy) butyramide
  参考文献：
  名称：

  Radiation-curable compound

  摘要：

  本发明涉及一种辐射可固化化合物，其为含有羟基烷酰胺基团和羟基的化合物的单价或多价羧酸酯，其中所述羧酸酯源自α，β-乙烯基不饱和羧酸。包含该化合物的涂层组合物具有高聚合速率并显示所需的化学和机械性能。

  公开号：

  US20010020050A1

文献信息

• [EN] TARGETED DELIVERY OF THERAPEUTICALLY ACTIVE COMPOUNDS<br/>[FR] ADMINISTRATION CIBLEE DE COMPOSES THERAPEUTIQUEMENT ACTIFS
  申请人：TRANSGENE SA

  公开号：WO2005039558A1

  公开（公告）日：2005-05-06

  A compound comprising: (i) A therapeutically active moiety and, (ii) A targeting moiety able to bind to a glutamine transporter.

  一种化合物，包括：(i) 一种治疗活性基团，以及 (ii) 一种能够结合到谷氨酰基转运蛋白的靶向基团。
• [EN] LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY<br/>[FR] CONJUGUÉ LIPIDIQUE PRÉPARÉ À PARTIR D'UN FRAGMENT SQUELETTE
  申请人：INTEGRATED NANOTHERAPEUTICS INC

  公开号：WO2020191477A1

  公开（公告）日：2020-10-01

  The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (lId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP).

  该应用涉及公式M-X1-L的脂质共轭物，其中M是感兴趣的分子，如药物基团；X1是连接基团，如酯、醚或氨基甲酸酯；L是由公式(lId)表示的脂质支架：-L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6，其中L包含5至40个碳原子和0至2个碳-碳双键。该脂质共轭物可以配制在药物传递载体中，如脂质纳米粒子（LNP）。
• [EN] POLYPEPTIDE-OPIOID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYPEPTIDES OPIOÏDES ET UTILISATIONS ASSOCIÉES
  申请人：ANGIOCHEM INC

  公开号：WO2013056096A1

  公开（公告）日：2013-04-18

  The invention features polypeptide-opioid conjugates capable of crossing the blood-brain barrier. The polypeptide-opioid conjugates can be used to treat a condition that is modulated by opioid receptors such as pain (e.g., postoperative pain, cancer pain, acute pain, and chronic pain).

  这项发明涉及能够穿越血脑屏障的多肽-阿片类肽共轭物。这些多肽-阿片类肽共轭物可用于治疗受阿片类受体调节的疾病，如疼痛（例如术后疼痛、癌症疼痛、急性疼痛和慢性疼痛）。
• [EN] NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF<br/>[FR] NANOPARTICULES POUR CHIMIOTHÉRAPIE, THÉRAPIE CIBLÉE, THÉRAPIE PHOTODYNAMIQUE, IMMUNOTHÉRAPIE ET N'IMPORTE QUELLE COMBINAISON DE CES DERNIÈRES
  申请人：UNIV CHICAGO

  公开号：WO2017201528A1

  公开（公告）日：2017-11-23

  Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

  含有脂质基团连接到药物衍生物的前药，例如通过含有二硫键的连接剂连接到抗癌药物衍生物的前药被描述。还描述了涂有含有前药的脂质层的纳米粒子，包含这些纳米粒子的配方，以及在治疗疾病的方法中使用这些纳米粒子，例如癌症，单独或与额外的药物化合物、靶向剂和/或免疫疗法剂联合使用，例如靶向CTLA-4、PD-1/PD-L1、IDO、LAG-3、CCR-7或其他途径的免疫抑制抑制剂，或者靶向这些途径的多种免疫抑制抑制剂的组合。可选地，纳米粒子可以包含光敏剂或其衍生物，并可用于涉及光动力疗法的方法。由所披露的纳米粒子和/或纳米粒子配方提供的多种疗法模式的组合导致协同治疗效果。
• OLIGOMER-CONTAINED NANOPARTICLE COMPLEX RELEASE SYSTEM
  申请人：National Yang Ming University

  公开号：US20140363490A1

  公开（公告）日：2014-12-11

  An oligomer-contained nanoparticle complex is provided. The oligomer-contained nanoparticle complex of the invention comprises (a) a nanoparticle, (b) a polymer with high molecule weigh, (c) a target molecule, (d) an oligomer, wherein the oligomer is crosslinked with the polymer by the intermolecular hydrogen bonds or electron bonds, and e) a space for active substances, wherein the space for active substances is encapsulated by the nanoparticle. The oligomer-contained nanoparticle complex of the invention has the high stability and fast drug release rate, and would not be largely accumulated in normal tissues. The invention also provides a method for preparing the oligomer-contained nanoparticle complex and the method for releasing drug.

  本发明提供了一种含有寡聚物的纳米颗粒复合物。该发明中的含有寡聚物的纳米颗粒复合物包括：(a)一种纳米颗粒，(b)一种高分子量聚合物，(c)一种目标分子，(d)一种寡聚物，其中寡聚物通过分子间氢键或电子键与聚合物交联，以及(e)一种活性物质的空间，其中活性物质的空间被纳米颗粒封装。本发明的含有寡聚物的纳米颗粒复合物具有高稳定性和快速释药率，并且不会在正常组织中大量积累。本发明还提供了制备含有寡聚物的纳米颗粒复合物的方法以及释药方法。